脂蛋白(a)[Lp(a)]结构类似于低密度脂蛋白(LDL),高水平Lp(a)是一种公认的心血管疾病危险因子。体内存在氧化型Lp(a)更易于促进动脉粥样硬化的发生发展。Lp(a)中的载脂蛋白(a)[apo(a)]存在异质性,研究显示其危险性可能是由于apo(a)等位基因水平差异引起的,而且apo(a)的多态性影响到Lp(a)水平的临床测定,如何降低apo(a)对结果的影响还需要更多深入研究。目前针对高Lp(a)水平的人群尚无统一的治疗标准,但降脂治疗有益于预防心脑血管疾病的发生。
Lipoprotein(a) is an atherogenic particle which structurally resembles low density lipoprotein.Elevated plasma concentrations of Lp(a) is an independent risk factor for atherosclerosis.Ox-Lp(a) has been reported to play a more potent role than native Lp(a) in atherosclerosis.Apolipoprotein(a) is heterogeneous,and the risk of Lp(a) may be due to the differences of apolipoprotein(a) allele level.The polymorphism of apolipoprotein(a) affects clinical determination of Lp(a) level.How to reduce the influence of heterogeneity still need more research.At present,there is no uniform standard treatment for the people with high Lp(a) level,but lipid-lowering therapy can prevent cardiovascular diseases.